1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Therapy

What Are the Most Profitable Therapies? Market Trends & Strategies Explained

  • Currently 5/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
1 vote

Topics under Therapy

Global Therapy Industry 

The global therapy industry (one large revenue center of the pharma industry) involves treatments intended to protect from, cure or manage specific illnesses. The treatment of each therapeutic area and its specific conditions varies widely.

Therapy is usually decided on once the patient has been diagnosed with a specific medical condition or disease, though therapies may also be preventive measures. Therapies applied following diagnosis are either abortive or supportive. The former is a curative measure that seeks to inhibit development of the condition, while the latter relieves the patient’s suffering due to the symptoms of the disease without treating the condition itself.

Preventive therapies are used to safeguard people against disease; for example, vaccinations are used to prevent infections such as polio, smallpox and measles.

Market Trends

The combined market for medicines and therapies (such as oncology) used in the treatment of disease is witnessing a slower rate of spending: in the five years up to 2010, spending on medicines grew by more than 6% yearly. However, in the five years up to 2015, the rate of growth is slowing to between 3% and 6%. Global spending on medicine and therapy in 2015 is forecast to reach $1.1 trillion, reports the IMS Institute for Healthcare and Informatics.

The market is to see increased spending on generic drugs, hitting almost 40% growth in 2015 or nearly doubling in a decade. Spending on brand-name medicines should drop by $120 billion in the five-year period ending in 2015.

Increased prevalence of type 2 diabetes, particularly in emerging markets such as China, Brazil and India, will see global spending on the disease rise 4%-7% through 2015, with oral antidiabetics increasingly favored. Spending on therapeutic medicine to treat asthma and chronic obstructive lung disease will drop from 9% in the five-year period ending in 2010 to 2%-5% from 2010 to 2015.

Therapy Spending Forecasts to 2015 *In US$ Billion 

Key Market Segments

According to a report by the IMS Institute for Healthcare Informatics, oncology will continue to hold the top spot in the therapies industry, with forecast revenue between $75 billion and $80 billion in 2015, representing a jump of more than $20 billion in a five-year period. Lipid regulators will fall from second to fourth place, reaching between $29 billion and $34 billion in the same period. Meanwhile, anti-diabetics will rise to second place at between $43 billion and $48 billion.

Respiratory agents are expected to remain the third-biggest seller, with a $5 billion to $10 billion increase on 2010 sales. Drugs to treat hypertension are forecast to rise to fifth place with an up to $6.5 billion increase in revenue. Overall, auto-immune drugs should see a substantial jump to reach between $27 billion and $32 billion by 2015.

HIV antivirals are expected to jump from tenth to seventh place with sales of between $20 billion and $24 billion by 2015. A substantial drop in market share is expected for antidepressants, from more than $20 billion in 2010 to between $13 billion and $16 billion in 2015.  Treatments for multiple sclerosis should rise several places in the same period, marking revenue from under $10 billion to between $12 billion and $15 billion. Antipsychotics are forecast to see a $5 billion drop to $20 billion in 2015.

Therapy segments expected to drop out of the top-20 list include vitamins and minerals, antirheumatics, cephalosporins, combs (antibiotics) and vaccines. Categories expected to appear in the top 20 include treatments for glaucoma, Alzheimer’s, osteoporosis and attention deficit hyperactivity disorder.

Categories expected to show less substantial fluctuation include narcotic analgesics, antiepileptics and erythropoietics.

Top 20 Global Therapeutic Categories (2015) 

Read more »

Share
24/7 Customer Support

Talk to Sam

+1 718 473 0872

1-10 of about 23 000 reports

Global Therapy Market - Forecast

  • August 2016
    5 pages
  • Therapy  

    Therapy  

    Anti-Infective  

  • India  

    World  

View report >

Therapy Market in the US

  • August 2016
    13 pages
  • Vaccine  

    HPV Vaccine  

  • United States  

View report >

Therapy Market in Europe

  • August 2016
    56 pages
  • Therapy  

  • Europe  

View report >

Blood Disease Statistics and Therapy Market in Asia and Canada

  • July 2016
    67 pages
  • Blood Disease  

    Therapy  

    Blood Supply  

  • Asia  

    Canada  

View report >

Therapy Market in Japan and Europe

  • July 2016
    7 pages
  • Therapy  

    Therapy  

  • Japan  

    Europe  

View report >

Therapy and Anti-Infective Market in France

  • July 2016
    14 pages
  • Therapy  

    Anti-Infective  

  • France  

View report >

Therapy Market in Germany

  • July 2016
    14 pages
  • Therapy  

  • Germany  

View report >

Therapy Market in Italy

  • July 2016
    11 pages
  • Therapy  

    Chemotherapy  

  • Italy  

View report >

Therapy Market in the UK

  • August 2016
    11 pages
  • Therapy  

  • United Kingdom  

View report >

Targeted Therapy Market in Canada and the US

  • August 2016
    15 pages
  • Targeted Therap...  

  • Canada  

    United States  

View report >


About 13 000 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 99 - $ 42 529)

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) ...

Myocardial Fibrosis - Pipeline Review, H1 2016

June 2016 $ 42 529

Sicca Syndrome (sjogren) - Pipeline Review, H1 2016

June 2016 $ 42 529

Kidney Cancer (renal Cell Cancer) - Pipeline Review, H1 ...

June 2016 $ 42 529

Retinitis Pigmentosa (retinitis) - Pipeline Review, H1 ...

June 2016 $ 42 529

Retinopathy - Pipeline Review, H1 2016

June 2016 $ 42 529

Hospital Acquired Methicillin-resistant Staphylococcus ...

June 2016 $ 42 529

Poliomyelitis - Pipeline Review, H1 2016

June 2016 $ 42 529

Hyperglycemia - Pipeline Review, H1 2016

June 2016 $ 42 529

Sangamo Biosciences, Inc. - Product Pipeline Review - 2 ...

June 2016 $ 42 529

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.